ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Vaccine RFAs Approved In Concept By NCI Advisors

July 26, 1991

Waxman Compromise Bill Clears House; Centers Line Item Traded For Guarantee Of Minimum Number of 55

November 25, 1983

BioMedicines Begins Kidney Cancer Study; EntreMed Moves Forward.

February 25, 2000

NCI Starts $2 Million Study On Cancer Patient Job Discrimination

January 17, 1975

Prevention Program Being Developed For Primary Providers

January 29, 1988

Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says

April 13, 1984